UK markets closed

AstraZeneca PLC (AZN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
71.04+0.91 (+1.29%)
As of 01:49PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 215.81B
Enterprise value 238.57B
Trailing P/E 36.81
Forward P/E 16.64
PEG ratio (5-yr expected) 0.89
Price/sales (ttm)4.78
Price/book (mrq)5.55
Enterprise value/revenue 5.21
Enterprise value/EBITDA 17.77

Trading information

Stock price history

Beta (5Y monthly) 0.19
52-week change 3-7.31%
S&P500 52-week change 323.06%
52-week high 376.56
52-week low 360.47
50-day moving average 366.25
200-day moving average 366.65

Share statistics

Avg vol (3-month) 36.19M
Avg vol (10-day) 35.94M
Shares outstanding 53.1B
Implied shares outstanding 63.12B
Float 81.54B
% held by insiders 10.00%
% held by institutions 116.83%
Shares short (28 Mar 2024) 47.66M
Short ratio (28 Mar 2024) 41.61
Short % of float (28 Mar 2024) 4N/A
Short % of shares outstanding (28 Mar 2024) 40.25%
Shares short (prior month 29 Feb 2024) 49.26M

Dividends & splits

Forward annual dividend rate 41.45
Forward annual dividend yield 42.07%
Trailing annual dividend rate 32.90
Trailing annual dividend yield 34.14%
5-year average dividend yield 42.52
Payout ratio 476.12%
Dividend date 325 Mar 2024
Ex-dividend date 422 Feb 2024
Last split factor 22:1
Last split date 327 Jul 2015

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 13.00%
Operating margin (ttm)16.92%

Management effectiveness

Return on assets (ttm)6.60%
Return on equity (ttm)15.64%

Income statement

Revenue (ttm)45.81B
Revenue per share (ttm)2.45
Quarterly revenue growth (yoy)7.30%
Gross profit (ttm)N/A
EBITDA 15.01B
Net income avi to common (ttm)5.95B
Diluted EPS (ttm)1.91
Quarterly earnings growth (yoy)6.50%

Balance sheet

Total cash (mrq)5.86B
Total cash per share (mrq)3.78
Total debt (mrq)29.65B
Total debt/equity (mrq)75.70%
Current ratio (mrq)0.82
Book value per share (mrq)25.25

Cash flow statement

Operating cash flow (ttm)10.34B
Levered free cash flow (ttm)9.5B